Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611423 | 0.86 | KDM4E (0.41) | MTNR1AMTNR1BNQO2OPRK1 | |
| SCHEMBL613681 | 0.85 | KDM4E (0.40) | MTNR1AMTNR1BNQO2OPRK1 | |
| SCHEMBL3861226 | 0.85 | MTNR1A (0.36) | MTNR1AMTNR1BNQO2OPRK1OPRD1 | |
| SCHEMBL4569062 | 0.82 | HIF1A (0.47) | MTNR1AMTNR1BOPRK1OPRD1CNR1 | |
| SCHEMBL17735444 | 0.82 | HIF1A (0.47) | MTNR1AMTNR1BOPRK1OPRD1CNR1 | |
| SCHEMBL614318 | 0.82 | MTNR1A (0.44) | MTNR1AMTNR1BNQO2OPRK1OPRD1 | |
| SCHEMBL612756 | 0.81 | CNR1 (0.41) | MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL4569064 | 0.81 | CNR1 (0.41) | MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL613174 | 0.81 | MTNR1A (0.41) | MTNR1AMTNR1BNQO2CNR1CNR2 | |
| SCHEMBL611414 | 0.81 | MTNR1A (0.37) | MTNR1AMTNR1BNQO2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018077-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018077-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | MTNR1A 383/4885MTNR1B 254/4885NQO2 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.